News & Videos - AMGEN INC AMGEN ORD (CDI) - English

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Feb. 4, 2025 THOUSAND OAKS, Calif. , Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver...

AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Jan. 31, 2025 THOUSAND OAKS, Calif. , Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call...

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Jan. 8, 2025 THOUSAND OAKS, Calif. , Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news...

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., Dec. 10, 2024 THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help...

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA PR Newswire THOUSAND OAKS, Calif., Dec. 5, 2024 Investment Establishes Second Facility in Holly Springs ; Builds on Previous $550M Commitment THOUSAND OAKS, Calif. , Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina . This brings the company's total planned investment in Holly Springs to more than $1.5 billion ,...

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE PR Newswire THOUSAND OAKS, Calif., Nov. 29, 2024 THOUSAND OAKS, Calif. , Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 . Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney...

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY PR Newswire THOUSAND OAKS, Calif., Nov. 26, 2024 MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study In People With Type 2 Diabetes Living With...

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM PR Newswire THOUSAND OAKS, Calif., Nov. 26, 2024 THOUSAND OAKS, Calif. , Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024 , to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will...

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT PR Newswire THOUSAND OAKS, Calif., Nov. 20, 2024 Howard Chang , M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer THOUSAND OAKS, Calif. , Nov. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Howard Chang , M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief...

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA PR Newswire THOUSAND OAKS, Calif., Nov. 13, 2024 THOUSAND OAKS, Calif. , Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our...

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Nov. 8, 2024 THOUSAND OAKS, Calif. , Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday , Nov. 13, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of...

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Oct. 30, 2024 THOUSAND OAKS, Calif. , Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas,"...

AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., Oct. 25, 2024 THOUSAND OAKS, Calif. , Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024 , to all stockholders of record as of the close of business on November 18, 2024 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to...

AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Oct. 24, 2024 THOUSAND OAKS, Calif. , Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert...

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE PR Newswire THOUSAND OAKS, Calif., Sept. 23, 2024 THOUSAND OAKS, Calif. , Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024 , to discuss new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA ® (inebilizumab-cdon) Phase 3 programs. Jay Bradner , executive vice president of Research...

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024 PR Newswire THOUSAND OAKS, Calif., Sept. 13, 2024 Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif. , Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The...

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 PR Newswire THOUSAND OAKS, Calif., Sept. 9, 2024 DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation...

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Aug. 30, 2024 THOUSAND OAKS, Calif. , Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday , Sept. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, will present at the...

AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Aug. 29, 2024 THOUSAND OAKS, Calif. , Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday , Sept. 4, 2024. Robert A. Bradway , chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be...

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., Aug. 6, 2024 THOUSAND OAKS, Calif. , Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth," said Robert A. Bradway , chairman and chief executive officer. Key results...